Metallo-β-lactamase-producing Pseudomonas aeruginosa (MPPA) is an important nosocomial pathogen that shows resistance to all β-lactam antibiotics except monobactams. There are various types of metallo-β-lactamases (MBLs) in carbapenem-resistant P. aeruginosa including Imipenemase (IMP), Verona integron-encoded metallo-β-lactamase (VIM), Sao Paulo metallo-β-lactamase (SPM), Germany imipenemase (GIM), New Delhi metallo-β-lactamase (NDM), Florence imipenemase (FIM). Each MBL gene is located on specific genetic elements including integrons, transposons, plasmids, or on the chromosome, in which they carry genes encoding determinants of resistance to carbapenems and other antibiotics, conferring multidrug resistance to P. aeruginosa. In addition, these genetic elements are transferable to other Gram-negative species, increasing the antimicrobial resistance rate and complicating the treatment of infected patients. Therefore, it is essential to understand the epidemiology, resistance mechanism, and molecular characteristics of MPPA for infection control and prevention of a possible global health crisis. Here, we highlight the characteristics of MPPA.
BackgroundTo investigate the risk factors for vaginal infections and antimicrobial susceptibilities of vaginal microorganisms among women who experienced preterm birth (PTB), we compared the prevalence of vaginal microorganisms between women who experienced preterm labor (PTL) without preterm delivery and spontaneous PTB.MethodsVaginal swab specimens from 126 pregnant women who experienced PTL were tested for group B streptococcus (GBS), Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma urealyticum, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, Treponema pallidum, herpes simplex virus (HSV) I and II, and bacterial vaginosis. A control group of 91 pregnant women was tested for GBS. Antimicrobial susceptibility tests were performed for GBS, M. hominis, and U. urealyticum.ResultsThe overall detection rates for each microorganism were: U. urealyticum, 62.7%; M. hominis, 12.7%; GBS, 7.9%; C. trachomatis, 2.4%; and HSV type II, 0.8%. The colonization rate of GBS in control group was 17.6%. The prevalence of GBS, M. hominis, and U. urealyticum in PTL without preterm delivery and spontaneous PTB were 3.8% and 8.7% (relative risk [RR], 2.26), 3.8% and 17.3% (RR, 4.52), and 53.8% and 60.9% (RR, 1.13), respectively, showing no significant difference between the 2 groups. The detection rate of M. hominis by PCR was higher than that by culture method (11.1% vs. 4.0%, P=0.010). The detection rates of U. urealyticum by PCR and culture method were 16.7% and 57.1%, respectively.ConclusionsThere was no significant difference in the prevalence of GBS, M. hominis, and U. urealyticum between the spontaneous PTB and PTL without preterm delivery groups.
The urushiol has an antibacterial effect against H. pylori infection and can be used safely for H. pylori eradication in a mouse model.
In a study designed to provide data on the rates of maternal carriage of group B streptococci (GBS) in Korean women, vaginal, anorectal, and urethral swab specimens from 459 pregnant women and ear canal and umbilicus swabs from their 288 neonates were cultured with new Granada medium and selective Todd-Hewitt broth. Additionally, the serotypes of 64 isolates of GBS and the minimal inhibitory concentrations of seven antimicrobial agents for these isolates were determined. The rate of colonization by GBS in pregnant women and in their babies was 5.9% (27/459) and 0.7% (2/288), respectively. The rates of resistance of GBS isolated from pregnant women were 13.3% to clindamycin, 5% to erythromycin, and 98.3% to tetracycline. The majority of GBS isolates from pregnant women belonged to serotypes Ib (48.3%), Ia (24.1%), and III (20.7%).
Aerococcus viridans, a catalase-negative gram-positive coccus rarely causing bacteremia, was isolated from blood cultures of a 52-yr-old man under the granulocytopenic condition. The isolate showed the typical characteristics of A. viridans, i.e., tetrad arrangements in gram stain, positive pyrrolidonyl aminopeptidase (PYR) and negative leucine aminopeptidase (LAP) reactions, and no growth at 45℃. The isolate was revealed to be highly resistant to penicillin, erythromycin, clindamycin, and ceftriaxone, although most strains of A. viridans isolated from the previously reported patients were susceptible to penicillin and other commonly used antibiotics. Even though A. viridans is rarely associated with human infections, it could be a potential causative agent of bacteremia, especially in immunocompromised patients.
Background:The prevalence of neonatal group B streptococcal infection depends mainly on the colonization rate of pregnant women by group B streptococci (GBS). Although the colonization rate of Korean women by GBS is considered lower than in other countries, recent data on the maternal colonization rate of GBS are sparse. Methods: From
In 540 beta-hemolytic streptococci, the rates of resistance to tetracycline, chloramphenicol, erythromycin, and clindamycin were 80.0, 22.8, 20.2, and 19.1%, respectively. Of the erythromycin-resistant isolates, 63.3% had the constitutive macrolide-lincosamide-streptogramin B (MLS B ) resistance phenotype, 23.9% had the M phenotype, and 12.8% had the inducible MLS B resistance phenotype. The constitutive MLS B resistance phenotype with the erm(B) gene was dominant in Korea.Current practice guidelines for the management of pharyngitis caused by Streptococcus pyogenes include the use of erythromycin as an alternative to penicillin when indicated and clindamycin for persons with multiple recurrent episodes (5). Macrolide or lincosamide therapy is also a recommended treatment option for S. agalactiae infection or for prophylaxis when streptococcal colonization among pregnant women is suspected (16). However, recent studies have shown that changes in the susceptibility of beta-hemolytic streptococci (BHS) to erythromycin and clindamycin have been substantial, although differences in rates of resistance to these agents have existed according to geographical location and investigators. The objectives of the present study were to investigate the incidence and possible trends in susceptibility among the BHS isolated from clinical specimens in a Korean hospital and to clarify the phenotypes and genotypes of erythromycin-resistant isolates.A total of 540 strains of BHS were collected from clinical specimens between January 1990 and December 2000 at Wonju Christian Hospital, a 1,000-bed teaching hospital in South Korea. Multiple isolates from the same patient were avoided. The isolates were identified by standard methods. Beta-hemolytic strains with group F antigens were excluded. Susceptibility to penicillin G, erythromycin, clindamycin, tetracycline, ceftriaxone (Sigma Chemical Co., St. Louis, Mo.), vancomycin (Daewoong Lilly, Seoul, Korea), and chloramphenicol (Chongkundang, Seoul, Korea) was tested by the agar dilution method (14). The resistance phenotypes of erythromycin-resistant (intermediate and resistant) isolates were determined by the double-disk test with erythromycin (15 g) and clindamycin (2 g) disks (17). The presence of erm and mef class genes was determined by PCR amplification with previously described primers (11,18) specific for erm(A) subclasses erm(TR), erm(B), erm(C), and mef(A).The overall resistance rates of BHS were found to be 80.0% for tetracycline, 22.8% for chloramphenicol, 20.2% for erythromycin, and 19.1% for clindamycin, whereas all isolates were susceptible to penicillin G, ceftriaxone, and vancomycin (Table 1). The rates of resistance to erythromycin found in this study were as follows, in order of decreasing rank: S. agalactiae, 25.3%; S. pyogenes, 16.1%; group C streptococci, 9.1%; group G streptococci, 9.0%. S. agalactiae had the highest rate of clindamycin resistance (28.2%), followed by S. pyogenes (9.8%), group C streptococci (4.5%), and group G streptococci (1.5%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.